Merck & Company Inc (MRK)
$99.90 -$1.10 (-1.08%) 12:11 PM 12/11/24
NYSE | $USD | Drug Manufacturers - GeneralStock Data
-
Market Cap
$260.78B -
Day's Range
$99.72 - $101.45 -
Volume
13,655,073 -
52 Week Low / High
$94.48 - $133.74 -
PE Ratio
21.57x -
PEG Ratio
0.07 -
Dividend Frequency
quarterly
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 16
- Strong Buy
- 5
- Buy
- 6
- Hold
- 0
- Sell
- 0
- Strong Sell
- $117.20
- Target Price
Company News
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Investors in Merck (NYSE:MRK) have seen respectable returns of 48% over the past three years — Oct 18th, 2024
It hasn't been the best quarter for Merck & Co., Inc. (NYSE:MRK) shareholders, since the share price has fallen 13% in that time. But that shouldn't obscure the pleasing returns achieved by shareholders over the last three years. After all, the share price is up a market-beating 35% in tha...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024
Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
-
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...
Portfolio
Comprised of 1 portfolios